GLP-1 Drug Shortages: Safe Alternatives and What to Avoid

The GLP-1 drug boom created a supply crisis that left millions of patients scrambling. Wegovy and Ozempic shortages beginning in 2022 and extending through 2024 drove an enormous compounded semaglutide market — pharmacies producing their own versions of the drug, often at lower cost and with varying quality. Then, in early 2025, the FDA formally declared the shortage resolved and began a phased crackdown on compounded semaglutide production, leaving many patients who had been relying on compounded versions facing abrupt access loss. The shortage situation has evolved rapidly, and navigating it safely — protecting your health while finding legitimate alternatives — requires understanding what is actually available, what the risks are, and how to protect your gut through any transition period.

The Supply Chain Situation: What Has Actually Changed

Novo Nordisk significantly increased semaglutide manufacturing capacity between 2023 and 2025, investing over $6 billion in expanded production globally. By mid-2025, the company reported that US demand for Wegovy (semaglutide 2.4mg, obesity indication) was being met reliably, and shortage designations were removed from the FDA's official drug shortage database. Ozempic (semaglutide for diabetes) supply remained tighter due to continued demand growth, but shortages were localized rather than systemic by late 2025.

Tirzepatide availability has followed a different trajectory. Eli Lilly's production scale-up for Mounjaro and Zepbound has been substantial, and as of 2026, tirzepatide is generally more consistently available than it was in 2023-2024. However, regional pharmacy-level shortages still occur with both drugs, particularly for higher dose strengths, because of supply chain dynamics at the distributor and retail pharmacy level. Patients who are established on a dose may intermittently face delays of days to weeks. Understanding what to do during these gaps — safely — is something every GLP-1 user should have planned in advance.

Compounded Semaglutide: The FDA Crackdown Explained

Compounded semaglutide — produced by 503A and 503B compounding pharmacies using bulk drug substances — was legal during the shortage period under FDA compounding exemptions that permit production of compounded versions of drugs on the official shortage list. Once the FDA removed semaglutide from the shortage list in February 2025, these exemptions ended, and compounding pharmacies were given a 90-day phase-out period to stop producing compounded semaglutide. The FDA issued warning letters to several large compounding operations and initiated enforcement actions against the largest online telehealth platforms that had been selling compounded semaglutide nationwide.

The crackdown does not mean compounded semaglutide has disappeared from the market — enforcement is imperfect and some operations continue to produce and sell it, particularly through online platforms outside FDA oversight. But patients obtaining compounded semaglutide after the shortage resolution are in a legally and medically ambiguous position. FDA-approved semaglutide (Ozempic, Wegovy) undergoes rigorous quality testing, standardized manufacturing, and lot-level verification. Compounded versions have no such standardized oversight. Independent laboratory testing of compounded semaglutide samples has found concentration variability of up to 20-30% from labeled doses, inadequate sterility assurance, and in some cases the presence of degraded drug products.

Dangerous Alternatives Being Sold Online: What to Avoid

The demand for GLP-1 drugs has created a predatory market for dangerous alternatives. Several categories of products are actively being sold with misleading GLP-1 claims that patients and providers should be aware of. The most dangerous are 'research chemical' semaglutide or tirzepatide sold through unregulated online vendors as 'for laboratory use only' — a legal fiction that circumvents pharmaceutical regulations. These products have been associated with multiple serious adverse events, including severe hypoglycemia (some preparations contain undisclosed insulin), anaphylactic reactions, and infections from non-sterile products.

A second category is oral 'GLP-1 supplements' marketed with claims about 'activating GLP-1 pathways naturally.' No oral supplement can replicate the pharmacological GLP-1 receptor agonism of semaglutide or tirzepatide. Some supplements do have modest evidence for modestly increasing endogenous GLP-1 secretion (berberine, fiber, certain amino acids) but their effect sizes are a small fraction of pharmaceutical GLP-1 drugs. Marketing these as GLP-1 alternatives is misleading and can lead patients to forgo effective treatment. A third category is counterfeit branded products sold through online pharmacies that do not require prescriptions — these may contain no active ingredient, incorrect doses, or dangerous substitutes.

Legitimate Next-Generation Alternatives Approaching Market

For patients who genuinely cannot access or afford current GLP-1 drugs, the near-term pipeline offers legitimate alternatives that may reach the market in 2026-2027. Oral tirzepatide is in Phase 3 trials following strong Phase 2 data, and if approved would offer a needle-free option for patients with injection aversion. Retatrutide, Eli Lilly's triple agonist (GLP-1, GIP, and glucagon receptors), showed approximately 24% body weight loss in Phase 2 trials and has entered Phase 3 — if approved, it would represent the most potent weight loss agent in the class. CagriSema (semaglutide + cagrilintide) from Novo Nordisk is in Phase 3 with comparable efficacy to retatrutide.

These newer agents are still years from widespread availability for most patients. In the near term, legitimate alternatives for patients facing access gaps include switching to available agents within the class (if your Wegovy is unavailable, Zepbound may be accessible), working with your prescriber on dose reduction to extend supply during shortages, and exploring patient assistance programs offered by Novo Nordisk (NovoCare) and Eli Lilly (Lilly Cares), which provide medications at reduced or no cost to qualifying patients based on income thresholds.

Lifestyle and Supplement Approaches That Partially Mimic GLP-1 Effects

While no supplement replaces pharmaceutical GLP-1 drugs, there are evidence-based lifestyle and nutritional strategies that modestly support endogenous GLP-1 secretion and address some of the same metabolic pathways. These approaches are meaningful as bridging strategies during shortage gaps, not replacements. High-fiber diets — particularly those rich in soluble fiber from legumes, oats, and vegetables — stimulate GLP-1 release from intestinal L-cells. Studies show that 30-40g/day of soluble fiber increases postprandial GLP-1 by approximately 20-40% compared to low-fiber diets. This is modest compared to pharmaceutical GLP-1 drugs, but clinically non-trivial.

Protein-rich meals stimulate GLP-1 secretion more potently than carbohydrate or fat-rich meals — prioritizing protein at each meal can meaningfully support satiety signaling. Berberine, a plant alkaloid studied primarily as a glucose-lowering agent, has modest evidence for increasing GLP-1 secretion and improving insulin sensitivity. It does not replicate the appetite suppression magnitude of GLP-1 drugs, but may help with glycemic stability during a gap in pharmaceutical therapy. For patients using GLP-1 drugs primarily for type 2 diabetes management, working with an endocrinologist to bridge with other antidiabetic agents (metformin, SGLT-2 inhibitors) during shortage gaps is the most important priority.

Protecting Your Gut Health Through Shortages and Transitions

Drug transitions — stopping, starting, or changing GLP-1 drugs — create a period of gut physiology flux that warrants extra attention. When stopping a GLP-1 drug, gastric emptying gradually returns toward baseline over two to four weeks. For patients who had developed constipation or slowed transit on the drug, this normalization may be accompanied by loose stools or diarrhea as motility rebounds. For patients with SIBO who had been managing it partially through dietary restriction enabled by appetite suppression, the return of appetite may require restarting prokinetic or dietary management strategies proactively.

When starting a new GLP-1 drug after a gap, the gut side effect profile of the transition period tends to be less severe than the initial start — the gut has some memory of previous drug exposure and adapts somewhat faster. Nevertheless, all the same principles of careful dose escalation, fiber-rich diet, adequate hydration, and prokinetic support during constipation episodes apply. If you have been tracking your gut symptoms using a SIBO or digestive health app, reviewing your symptom history from when you first started your GLP-1 drug can help you anticipate what to expect and manage it more effectively.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.